Streetbeat News

Price Targets

SGH

Needham analyst Rajvindra Gill maintains a Buy rating on SMART Global Holdings (NASDAQ:SGH) and raises the price target from $32 to $37.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 11:53 am

WEAV

Raymond James analyst Alexander Sklar maintains an Outperform rating on Weave Communications (NYSE:WEAV) and raises the price target from $6 to $13.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 11:43 am

NKE

Raymond James analyst Rick Patel has maintained an 'Outperform' rating on Nike (NYSE:NKE) but lowered the price target from $135 to $128.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 11:42 am

UNCY

EF Hutton analyst Elemer Piros has reiterated a 'Buy' rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 11:07 am

XPEV

XPeng's stock has been upgraded from Buy to Outperform by CLSA, with the price target raised from $10 to $13.1. This has resulted in XPeng shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 11:02 am

SGH

Rosenblatt analyst Kevin Cassidy has reiterated a 'Buy' rating on SMART Global Holdings (NASDAQ:SGH) and maintained a price target of $35.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 11:01 am

CCL

CUK

Carnival Corporation's shares are trading higher following an upgrade from Jefferies, which changed its rating from 'Hold' to 'Buy' and increased the price target from $9 to $25.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 11:00 am

KYMR

Truist Securities analyst Srikripa Devarakonda has initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and a price target of $50.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:42 am

USPH

B of A Securities analyst Joanna Gajuk has initiated coverage on US Physical Therapy (NYSE:USPH) with a Buy rating and a price target of $138.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:41 am

CLB

Citigroup analyst Scott Gruber has downgraded Core Laboratories (NYSE:CLB) from Neutral to Sell and lowered the price target from $22 to $21.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 10:39 am